Market Intelligence, Clinical Progress, and High-Purity Reagents for Extracellular Matrix and Tumor Microenvironment Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNXB drug discovery. Select your therapeutic modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNXB Recombinant Fragment Protein (HEK293 expressed, covering active C-terminal FBG domain). High purity (>95%), Endotoxin controlled. Sequence Verified. | View TNXB Products |
| Gene Delivery | TNXB Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and functional overexpression. | View TNXB Products |
| Benchmark Ab | Anti-TNXB Recombinant Antibody. High-affinity positive control for ELISA, Western Blot, and IHC. | View TNXB Products |
| Validator | TNXB siRNA Set. For highly specific knockdown verification in cell-based assays. | View TNXB Products |
| Related Target A | Tenascin-C (TNC). Homologous family member; crucial counter-screening target for selectivity. | View TNC Products |
| Related Target B | TGF-beta 1 (TGFB1). Downstream signaling partner in tissue remodeling and epithelial-mesenchymal transition (EMT). | View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Massive Molecular Weight (450 kDa full-length) | Domain-specific recombinant fragments (EGF-like & Fibrinogen-like domains) optimized for high yield and structural stability. |
| Family Homology (Tenascin-C Cross-reactivity) | Sequence-verified human TNXB and TNC proteins available for comparative ELISA and cross-reactivity screening. |
| Lack of Controls | Sequence-defined recombinant positive control antibodies and validated siRNA sets included. |
| False Positives in ECM Binding | HEK293-expressed proteins ensuring native eukaryotic glycosylation patterns to prevent non-specific binding. |
Live Tenascin-X (TNXB) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Tenascin-X (TNXB) therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted tissue-remodeling therapies. As first-generation extracellular matrix (ECM) modulating therapies reach the clinic, the next wave of R&D is targeting TNXB's dual role in connective tissue disorders (such as Ehlers-Danlos Syndrome) and its emerging regulatory functions in the tumor microenvironment (TME).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / mRNA | Academic Medical Centers, Rare Disease Biotechs | Ehlers-Danlos Syndrome (EDS) classical-like type 1 | Lentivirus-mediated rescue assays (Need stable ORF transduction) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Solid Tumors (TME remodeling, EMT inhibition) | Functional blocking assays (Need high-purity recombinant TNXB domains) |
| Small Molecule Inhibitors | Fibrosis & Inflammation Specialists | Organ Fibrosis, Myocardial Infarction remodeling | Selectivity profiling against Tenascin-C (Need recombinant TNC/TNXB panels) |